Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EPS (Weighted Average and Diluted) (2018 - 2025)

Organogenesis Holdings has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at $0.27 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.27 for Q4 2025, up 575.0% from a year ago — trailing twelve months through Dec 2025 was $0.11 (up 650.0% YoY), and the annual figure for FY2025 was $0.15, up 1600.0%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.27 at Organogenesis Holdings, up from $0.11 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ORGO hit a ceiling of $0.38 in Q4 2021 and a floor of -$0.17 in Q1 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.04 (2023), compared with a mean of $0.05.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 1130.07% in 2023 and later crashed 750.0% in 2025.
  • Organogenesis Holdings' EPS (Weighted Average and Diluted) stood at $0.38 in 2021, then plummeted by 84.21% to $0.06 in 2022, then plummeted by 107.13% to -$0.0 in 2023, then surged by 1034.84% to $0.04 in 2024, then soared by 575.0% to $0.27 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.27 (Q4 2025), $0.11 (Q3 2025), and -$0.1 (Q2 2025) per Business Quant data.